NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar disorder in children and adolescents

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors Bristol Myers Squibb and Otsuka Pharmaceuticals (aripiprazole) Patient/carer groups Action for Children Action for Sick Children Afiya Trust Black Health Agency Changes Children's Society Chinese Mental Health Association Equalities National Council Matthew Trust MDF The Bipolar Organisation Mental Health Foundation Mental Health Matters Mental Health Providers Forum MIND Muslim Council of Britain Muslim Health Network National Children's Bureau National Parent Partnership Network National Perceptions Forum Rethink SANE South Asian Health Foundation Specialised Healthcare Alliance Together United Response WellChild YoungMinds	 General Board of Community Health Councils in Wales British National Formulary Care Quality Commission Commissioning Support Appraisals Service Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency Mental Health Act Commission National Association of Primary Care National Mental Health Development Unit National Pharmacy Association NHS Alliance NHS Commercial Medicines Unit NHS Confederation Public Health Wales NHS Trust Scottish Medicines Consortium Comparator manufacturers Accord Healthcare Ltd. (olanzapine, risperidone) Actavis UK (olanzapine, risperidone) Aspire Pharma UK (olanzapine) AstraZeneca (quetiapine) Beacon Pharmaceuticals (valproate) Consilient Health Ltd. (olanzapine, risperidone)
	Dexcel Pharma (risperidone)Dr. Reddy's Laboratories (olanzapine)

National Institute for Health and Clinical Excellence Matrix for aripiprazole for the treatment of acute manic and mixed episodes in children with bipolar disorder

Issue date: April 2012 Page 1 of 4

Consultees Commentators (no right to submit or appeal) Professional groups GlaxoSmithKline (lithium) Association for Young People's Health Janssen (risperidone) British Association for Counselling and Lilly (olanzapine) Psychotherapy Mylan UK (olanzapine, risperidone) British Association for Norgine Pharmaceuticals Ltd. (lithium) Psychopharmacology Sandoz (olanzapine, risperidone) British Association of Behavioural and sanofi (lithium, risperidone, valproate) Cognitive Psychotherapies Teva UK (olanzapine) British Association of Winthrop Pharmaceuticals (valproate) **Psychotherapists** Wockhardt Uk Ltd. (valproate) British Confederation of Zentiva (olanzapine) **Psychotherapists** British Neuropsychiatry Association Relevant research groups British Psychological Society Institute of Psychiatry College of Mental Health Pharmacy MRC Clinical Trials Unit Counsellors and Psychotherapists in National Institute for Health Research **Primary Care** National Primary Care Research & Mental Health Nurses Association **Development Centre** Primary Care Mental Health Education Royal College of General Practitioners **Evidence Review Group** Royal College of Nursing National Institute for Health Research Royal College of Paediatrics and Child Health Technology Assessment Health Programme Royal College of Pathologists School of Health & Related Research Royal College of Physicians Sheffield (ScHARR) Royal College of Psychiatrists Royal Pharmaceutical Society Associated Guideline groups National Clinical Guidelines Centre Royal Society of Medicine – Intellectual Disabilities Forum Associated Public Health groups United Kingdom Clinical Pharmacy Association None United Kingdom Council for Psychotherapy Others Department of Health Southampton, Hampshire, Isle of Wight & Portsmouth PCT Cluster South East London PCT Cluster Welsh Government

Issue date: April 2012 Page 2 of 4

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Issue date: April 2012 Page 3 of 4

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies;

Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence Matrix for aripiprazole for the treatment of acute manic and mixed episodes in children with bipolar disorder

Issue date: April 2012 Page 4 of 4

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.